Study of Zavicefta safety after it’s used in Korea
Part of Infections, Lungs & breathing clinical trials.
This study looks at how the antibiotic Zavicefta is doing after it’s been approved and used by doctors in Korea. It may help confirm its safety and appropriate use for certain serious infections.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 3 months or older (or an adult for some parts of the study)
- You already received at least one dose of Zavicefta for a serious infection like abdominal infection, urinary infection, or hospital pneumonia
- Your infection type matches one of these: complicated abdominal infection, complicated urinary infection (including kidney infection), hospital-acquired pneumonia (including on ventilators), or certain difficult-to-treat infections
- If you are an adult (19+), you may also qualify if you were treated for bloodstream infection linked to those infections
- You have not taken Zavicefta before (this is your first time receiving it)
- You signed the study data privacy statement
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
This study tests a new IV antibiotic combination (cefepime-enmetazobactam) for children with complicated urinary tract infections or kidney infections. The goal is to see how well it works and if it is safe.
This trial tests a specific antibiotic combination (ceftazidime-avibactam) in patients with serious infections that are resistant to other antibiotics, while they are in intensive care. The goal is to see how well this treatment works for critically ill patients.
This study tests whether combining two antibiotics (ceftazidime and fosfomycin) works better than ceftazidime alone for hospitalized adults with serious bacterial infections. If you have a severe infection thought to be caused by Gram-negative bacteria, this trial may offer a new treatment option.
This study looks at how a certain antibiotic (ceftazidime-avibactam) works in people with blood cancers or stem cell transplants, and how the drug levels affect the bacteria. It aims to find the best dosing to fight infections and reduce resistance.
This study is looking at how well two strong antibiotics (ceftazidime/avibactam and cefiderocol) work, with or without another drug called fosfomycin, for treating tough Gram-negative infections. It aims to help doctors understand the best way to use these medicines.
Hear when a new Hospital-acquired Pneumonia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.